7.30
7.30 (0%)
As of Feb 14, 2025
Regenxbio Inc [RGNX]
Source:
Company Overview
Regenxbio Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
| Country | United States |
| Headquarters | rockville, maryland |
| Phone Number | (240) 552-8181 |
| Industry | manufacturing |
| CEO | Kenneth T. Mills |
| Website | www.regenxbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $83.3 |
| Operating Profit | $-233.3 |
| Net Income | $-227.1 |
| Net Cash | $23 |
Profit Ratios
| Gross Margin | $49.8 |
| Operating Margin | -280 |
| Profit as % of Revenues | -21.9% |
| Profit as % of Assets | -43.7% |
| Profit as % of Stockholder Equity | -87.5% |
Management Effectiveness
| Return on Equity | -87.5% |
| Return on Assets | -48.7% |
| Turnover Ratio | 16% |
| EBITA | $-233.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $466 |
| Total Liabilities | $206.3 |
| Operating Cash Flow | $-173.1 |
| Investing Cash Flow | $103.4 |
| Financing Cash Flow | $92.7 |
